Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05897268
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT05896059
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)
- Conditions
- Interventions
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05893056
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 62
- Registration Number
- NCT05880082
- Locations
- 🇨🇳
Army Medical Center of the People's Liberation Army, Chongqing, Chongqing, China
The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05877001
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Weijia Fang, MD
- Target Recruit Count
- 30
- Registration Number
- NCT05862168
- Locations
- 🇨🇳
First affiliated hospital, School of Medicine, Zhejiang University, Hangzhou, China
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-09
- Target Recruit Count
- 25
- Registration Number
- NCT05841134
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 309
- Registration Number
- NCT05833984
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China
🇨🇳The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05823987
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05822453
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.